These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 9164221

  • 1. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 2. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 3. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 4. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R.
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [Abstract] [Full Text] [Related]

  • 5. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 6. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 7. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 8. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 10. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K, Klausmann M, Wolf M, Fischer JR, Drings P, Oster W.
    J Cancer Res Clin Oncol; 1991 Nov 01; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [Abstract] [Full Text] [Related]

  • 11. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 01; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 12. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
    Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R.
    Cancer; 1999 Feb 15; 85(4):855-63. PubMed ID: 10091762
    [Abstract] [Full Text] [Related]

  • 13. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T.
    J Natl Cancer Inst; 2001 Feb 21; 93(4):300-8. PubMed ID: 11181777
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 21; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 15. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug 21; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 21; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 17. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D, Jelić S, Radulović S.
    Srp Arh Celok Lek; 2000 Aug 21; 128(3-4):75-9. PubMed ID: 10932613
    [Abstract] [Full Text] [Related]

  • 18. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT, Roon R, Ferguson J, Martinez L, Stidley CA, Neidhart JA.
    Biotechnol Ther; 1993 Aug 21; 4(3-4):183-95. PubMed ID: 8292969
    [Abstract] [Full Text] [Related]

  • 19. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr 21; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 20. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J, Herndon JE, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.
    Clin Drug Investig; 2006 Apr 21; 26(5):257-66. PubMed ID: 17163259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.